CN106635987B - 一种体外高效扩增nk细胞的方法及其应用 - Google Patents
一种体外高效扩增nk细胞的方法及其应用 Download PDFInfo
- Publication number
- CN106635987B CN106635987B CN201611225377.2A CN201611225377A CN106635987B CN 106635987 B CN106635987 B CN 106635987B CN 201611225377 A CN201611225377 A CN 201611225377A CN 106635987 B CN106635987 B CN 106635987B
- Authority
- CN
- China
- Prior art keywords
- cell
- amplification
- interleukin
- days
- antigen presenting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000000822 natural killer cell Anatomy 0.000 title claims abstract description 104
- 230000003321 amplification Effects 0.000 title claims abstract description 66
- 238000003199 nucleic acid amplification method Methods 0.000 title claims abstract description 66
- 238000000034 method Methods 0.000 title claims abstract description 32
- 210000004027 cell Anatomy 0.000 claims abstract description 84
- 102100030703 Interleukin-22 Human genes 0.000 claims abstract description 46
- 108010074109 interleukin-22 Proteins 0.000 claims abstract description 45
- 210000000612 antigen-presenting cell Anatomy 0.000 claims abstract description 16
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims abstract description 16
- 238000011282 treatment Methods 0.000 claims abstract description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 10
- 230000005855 radiation Effects 0.000 claims abstract description 10
- 239000001963 growth medium Substances 0.000 claims abstract description 9
- 239000007788 liquid Substances 0.000 claims abstract description 7
- 238000000432 density-gradient centrifugation Methods 0.000 claims abstract description 6
- 210000005259 peripheral blood Anatomy 0.000 claims abstract description 6
- 239000011886 peripheral blood Substances 0.000 claims abstract description 6
- 239000012997 ficoll-paque Substances 0.000 claims abstract description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 5
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 claims abstract description 4
- 238000005138 cryopreservation Methods 0.000 claims abstract description 4
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 claims description 44
- 108010082808 4-1BB Ligand Proteins 0.000 claims description 41
- 108010074108 interleukin-21 Proteins 0.000 claims description 29
- 102100030704 Interleukin-21 Human genes 0.000 claims description 28
- 210000000170 cell membrane Anatomy 0.000 claims description 21
- 102000055501 telomere Human genes 0.000 claims description 16
- 108091035539 telomere Proteins 0.000 claims description 16
- 210000003411 telomere Anatomy 0.000 claims description 16
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- 230000013011 mating Effects 0.000 claims description 11
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 8
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 7
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 7
- 210000001519 tissue Anatomy 0.000 claims description 7
- 241000700605 Viruses Species 0.000 claims description 6
- 108020001507 fusion proteins Proteins 0.000 claims description 3
- 102000037865 fusion proteins Human genes 0.000 claims description 3
- 238000012545 processing Methods 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108091005703 transmembrane proteins Proteins 0.000 claims description 2
- 102000035160 transmembrane proteins Human genes 0.000 claims description 2
- 101000638251 Homo sapiens Tumor necrosis factor ligand superfamily member 9 Proteins 0.000 claims 3
- 230000032677 cell aging Effects 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 20
- 210000004881 tumor cell Anatomy 0.000 description 8
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 230000003712 anti-aging effect Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 2
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000012531 culture fluid Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 108010013534 Auxilins Proteins 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102100038077 CD226 antigen Human genes 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 241000175212 Herpesvirales Species 0.000 description 1
- 101000884298 Homo sapiens CD226 antigen Proteins 0.000 description 1
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 description 1
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 description 1
- 108010004222 Natural Cytotoxicity Triggering Receptor 3 Proteins 0.000 description 1
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 description 1
- 102100032852 Natural cytotoxicity triggering receptor 3 Human genes 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 101000980463 Treponema pallidum (strain Nichols) Chaperonin GroEL Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 108091008042 inhibitory receptors Proteins 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 229960002378 oftasceine Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/30—Coculture with; Conditioned medium produced by tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
- C12N2506/115—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells from monocytes, from macrophages
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611225377.2A CN106635987B (zh) | 2016-12-27 | 2016-12-27 | 一种体外高效扩增nk细胞的方法及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611225377.2A CN106635987B (zh) | 2016-12-27 | 2016-12-27 | 一种体外高效扩增nk细胞的方法及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106635987A CN106635987A (zh) | 2017-05-10 |
CN106635987B true CN106635987B (zh) | 2019-11-08 |
Family
ID=58832602
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201611225377.2A Active CN106635987B (zh) | 2016-12-27 | 2016-12-27 | 一种体外高效扩增nk细胞的方法及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106635987B (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107400659A (zh) * | 2017-09-25 | 2017-11-28 | 滨州医学院 | 一种nk细胞的培养方法 |
CN108815186A (zh) * | 2018-06-14 | 2018-11-16 | 上海鸣大生物科技有限公司 | 一种治疗hpv持续感染引起疾病的药物及制备方法与应用 |
CN110079499A (zh) * | 2019-05-07 | 2019-08-02 | 青岛大学附属医院 | Nk细胞的分离培养及保存入库的方法 |
CN110195041B (zh) * | 2019-06-20 | 2023-04-25 | 威海正生生物科技有限公司 | 利用ASC三维培养体系获得高活性Tregs细胞的方法 |
CN112501104B (zh) * | 2020-12-23 | 2022-09-09 | 杭州中赢生物医疗科技有限公司 | 基因工程细菌及其在淋巴细胞扩增中的应用 |
CN112430573B (zh) * | 2020-12-23 | 2023-03-14 | 杭州中赢生物医疗科技有限公司 | 一种nk细胞的培养体系及培养方法 |
CN112553157B (zh) * | 2020-12-23 | 2023-07-07 | 杭州中赢生物医疗科技有限公司 | 一种淋巴细胞的扩增体系及扩增方法 |
CN115197909B (zh) * | 2021-04-12 | 2023-11-17 | 北京和斯瑞生物技术有限公司 | 一种nk细胞的体外培养方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105567634A (zh) * | 2016-01-27 | 2016-05-11 | 上海润泉生物技术有限公司 | 一种用于nk细胞体外扩增的培养基及nk细胞体外扩增的方法 |
-
2016
- 2016-12-27 CN CN201611225377.2A patent/CN106635987B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105567634A (zh) * | 2016-01-27 | 2016-05-11 | 上海润泉生物技术有限公司 | 一种用于nk细胞体外扩增的培养基及nk细胞体外扩增的方法 |
Non-Patent Citations (1)
Title |
---|
建立改良型人NK 细胞体外扩增技术;李亚芬等;《免疫学杂志》;20150331;第31卷(第3期);250-255 * |
Also Published As
Publication number | Publication date |
---|---|
CN106635987A (zh) | 2017-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106635987B (zh) | 一种体外高效扩增nk细胞的方法及其应用 | |
CN105949325B (zh) | 包含cd27胞内结构域的嵌合抗原受体、慢病毒载体及其应用 | |
JP5358683B2 (ja) | ナチュラルキラー細胞の増殖方法 | |
AU2006288348B2 (en) | Method for activation treatment of antigen-presenting cell | |
EA016168B1 (ru) | Способ получения т-клеточной популяции и ее применение | |
CN109536455B (zh) | 一种car-nk细胞及其制备方法和应用 | |
CN105296431B (zh) | 肿瘤结合特异性γδTCR基因修饰的αβT细胞及其抑癌用途 | |
CN108379569B (zh) | 高效荷载肿瘤抗原的dc疫苗及其诱导扩增肿瘤抗原特异性ctl的方法 | |
CN108884440A (zh) | 用于增强免疫疗法的抗肿瘤活性的间充质干细胞 | |
CN105176927A (zh) | 一种细胞毒性增强的高效靶向杀伤nk/cik细胞的制备方法 | |
CN105087488A (zh) | 一种肿瘤抗原诱导的dc-cik细胞的制备方法及应用 | |
CN104262459B (zh) | 一种急性单核细胞白血病相关抗原mlaa‑34 表位多肽及其疫苗和制药应用 | |
WO2018088875A2 (ko) | 외래 미토콘드리아를 포함하는 자연살해세포 및 이를 포함하는 약학적 조성물 | |
CN110055269B (zh) | 人间皮素嵌合抗原受体、其t细胞及其制备方法和用途 | |
CN106574241A (zh) | 癌症免疫疗法组合物和方法 | |
CN109679902A (zh) | 一种基于cik免疫细胞的体外诱导扩增方法 | |
Tian et al. | Non-invasive T cells adoptive immunotherapy for solid tumor with gel anti-tumor T-cell injections | |
CN111849914A (zh) | 一种用于杀伤肿瘤的tcr-t细胞及其制备方法和应用 | |
JP2023052704A (ja) | がんを殺傷する細胞 | |
CN110526981B (zh) | 一种抗CD3和EpCAM双特异性抗体及其在治疗肺癌中的应用 | |
CN110358737A (zh) | 一种利用外泌体制备嵌合抗原受体t淋巴细胞的方法 | |
CN107019703A (zh) | LSECtin在作为治疗和/或预防埃博拉病毒的靶点中的应用 | |
CN113355283A (zh) | 基于rna疫苗的抗原反应性t细胞的制备方法及应用 | |
CN109790224A (zh) | Cacna1h衍生的肿瘤抗原多肽及其应用 | |
WO2020164167A1 (zh) | 一种用于通用型car-t制备的重组腺相关病毒载体及其构建方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240223 Address after: Unit 201-3, C22 Building, No. 218 Xinghu Street, Suzhou Industrial Park, Suzhou City, Jiangsu Province, 215000 Patentee after: Suzhou Qingyuan Biomedical Technology Co.,Ltd. Country or region after: China Address before: 315301 No.1, Xinxing 1st Road, Zonghan street, Xinxing Industrial Cluster District, Cixi City, Ningbo City, Zhejiang Province Patentee before: NINGBO FENGLIN BIOTECHNOLOGY CO.,LTD. Country or region before: China |